- Topic1/3
38k Popularity
40k Popularity
42k Popularity
51k Popularity
21k Popularity
- Pin
- 📢 Gate Square #Creator Campaign Phase 2# is officially live!
Join the ZKWASM event series, share your insights, and win a share of 4,000 $ZKWASM!
As a pioneer in zk-based public chains, ZKWASM is now being prominently promoted on the Gate platform!
Three major campaigns are launching simultaneously: Launchpool subscription, CandyDrop airdrop, and Alpha exclusive trading — don’t miss out!
🎨 Campaign 1: Post on Gate Square and win content rewards
📅 Time: July 25, 22:00 – July 29, 22:00 (UTC+8)
📌 How to participate:
Post original content (at least 100 words) on Gate Square related to
- 📢 Gate Square #MBG Posting Challenge# is Live— Post for MBG Rewards!
Want a share of 1,000 MBG? Get involved now—show your insights and real participation to become an MBG promoter!
💰 20 top posts will each win 50 MBG!
How to Participate:
1️⃣ Research the MBG project
Share your in-depth views on MBG’s fundamentals, community governance, development goals, and tokenomics, etc.
2️⃣ Join and share your real experience
Take part in MBG activities (CandyDrop, Launchpool, or spot trading), and post your screenshots, earnings, or step-by-step tutorials. Content can include profits, beginner-friendl
Global Real-World Study Results of the Largest-scale JAK1 Inhibitor Released
On March 8th, Jinshi Data reported that at the recent AAD meeting in the United States, the interim results of the world's largest JAK1 inhibitor, Abrocitinib, in the real world study AHEAD (Abrocitinib CHinese rEgistry on AD) were internationally released. This provides more real-world research and medical evidence data for the innovative small molecule drug with high selectivity JAK1 inhibitor in the field of atopic dermatitis (AD), further strengthening the clinical scientific basis to optimize treatment strategies and drive the reshaping of AD diagnosis and treatment pathways.